SHANGHAI – Innovative Cellular Therapeutics Co. Ltd. (ICT), of Shanghai, a leader among China's pack of emerging CAR T oncology companies, has struck a partnership deal with Vericel Corp., the first biotech to receive FDA approval for a tissue-engineered autologous cell scaffold.